Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

3.4%

5 terminated/withdrawn out of 147 trials

Success Rate

90.9%

+4.3% vs industry average

Late-Stage Pipeline

13%

19 trials in Phase 3/4

Results Transparency

1 of 50 completed trials have results

Key Signals

29 recruiting1 with results

Enrollment Performance

Analytics

N/A

50(46.3%)

Phase 2

29(26.9%)

Phase 4

16(14.8%)

Phase 1

7(6.5%)

Early Phase 1

3(2.8%)

Phase 3

3(2.8%)

108Total

N/A(50)

Phase 2(29)

Phase 4(16)

Phase 1(7)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (147)

Showing 20 of 147 trials

NCT06139692Phase 4Completed

Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke

Role: lead

NCT03324698Active Not Recruiting

The Natural History of Chronic Pancreatitis

Role: collaborator

NCT06097962Early Phase 1Recruiting

Safety and Efficacy of NK510 to Treat NSCLC

Role: collaborator

NCT07809178Not Yet Recruiting

China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

Role: collaborator

NCT06700863Completed

Screening of Biomarkers and Related Mechanisms for RIX

Role: collaborator

NCT05781243Phase 4Completed

Normal Saline Versus Lactated Ringer's Solution for Acute Pancreatitis Resuscitation

Role: collaborator

NCT07769827Not ApplicableRecruiting

Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC

Role: lead

NCT03115931Completed

The Effect of Perioperative Nutritional Assessment and Nutritional Support on Clinical Outcomes

Role: lead

NCT07615348Phase 2Recruiting

CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

Role: lead

NCT06205888Withdrawn

To Compare the Clinical Application of 18F-LNC1007 Injection PET/CT and 18F-FDG PET/CT

Role: lead

NCT07611825Phase 2Recruiting

Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma

Role: lead

NCT07297238Not ApplicableCompleted

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

Role: lead

NCT07672860Phase 2Recruiting

Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors

Role: lead

NCT07630090Phase 4Not Yet Recruiting

Gastric Feeding for the Prevention of Stroke-Associated Pneumonia

Role: lead

NCT07615907Not ApplicableNot Yet Recruiting

A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer

Role: lead

NCT04786743Not ApplicableCompleted

Timing of Endoscopic Intervention for Acute Variceal Hemorrhage: an RCT

Role: lead

NCT07571551Phase 2Recruiting

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

Role: lead

NCT06025305Enrolling By Invitation

Identifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography

Role: lead

NCT05903560Not ApplicableRecruiting

Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion

Role: lead

NCT06114940Phase 2Terminated

Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)

Role: lead